What Happened

Evommune's Phase 2b trial for EVO756 in chronic spontaneous urticaria (CSU) failed to meet its primary endpoint. The company will discontinue development for CSU but continues trials in atopic dermatitis (AD) and migraine.

Who Is Affected

Biotech and pharma companies in the chronic inflammation space, especially those targeting AD, migraine, or urticaria. Clinical researchers and investors following Evommune's pipeline will reassess timelines.

Market Impact

• Creates white space in MRGPRX2-targeted therapies for AD and migraine
• Reduces near-term competition in CSU treatments
• Validates IL-18BP pathway (EVO301) as viable for AD

What to Watch

EVO756 Phase 2b AD data expected Q3 2026. EVO301 Phase 2b AD trial progression. Monitor for partnership announcements as Evommune has cash runway through 2028.